A month has gone by since the last earnings report for Intra-Cellular Therapies (ITCI) . Shares have lost about 2.7% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Intra-Cellular due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. Intra-Cellular Q2 Loss Narrower Than ...